Drugs that contain Estradiol; Progesterone
1. Bijuva patents expiration
BIJUVA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846649 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9006222 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11793819 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11529360 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8987237 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10675288 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8846648 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9114145 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9301920 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11033626 | MAYNE PHARMA | Progesterone formulations having a desirable pk profile |
Nov, 2032
(8 years from now) | |
| US10806740 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8933059 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11103513 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11166963 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8993549 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8993548 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10206932 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8633178 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9114146 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10052386 | MAYNE PHARMA | Progesterone formulations |
Nov, 2032
(8 years from now) | |
| US11110099 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11103516 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10639375 | MAYNE PHARMA | Progesterone formulations |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2021 |
Market Authorisation Date: 28 December, 2021
Treatment: Treatment of menopause symptoms, including vasomotor symptoms
Dosage: CAPSULE;ORAL
How can I launch a generic of BIJUVA before it's drug patent expiration?
More Information on Dosage
BIJUVA family patents
